Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dilated Cardiomyopathy Therapeutic Drugs and Its Application

A dilated cardiomyopathy and therapeutic drug technology, which is applied in the dilated cardiomyopathy therapeutic drug and its application field, can solve the problems of dilated cardiomyopathy ineffectiveness and other problems, and achieve the effect of easy promotion and use, strong expressiveness, and easy operation

Active Publication Date: 2021-05-11
THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The present invention aims to solve the problem that the effect of dilated cardiomyopathy treatment drugs and methods in the prior art is not obvious, and proposes substances and applications for treating dilated cardiomyopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dilated Cardiomyopathy Therapeutic Drugs and Its Application
  • Dilated Cardiomyopathy Therapeutic Drugs and Its Application
  • Dilated Cardiomyopathy Therapeutic Drugs and Its Application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Such as figure 1 A schematic diagram of a wild-type zebrafish embryo is shown, as indicated by the arrow.

[0033] In order to better verify the therapeutic effect of CFTR enhancers on dilated cardiomyopathy, a dilated cardiomyopathy model was first established. Such as figure 2 As shown, the dilated cardiomyopathy model can well simulate the abnormalities and treatment conditions of dilated cardiomyopathy, such as figure 2 Where the arrow points, the heart is enlarged. If the Tang model of dilated cardiomyopathy behaves as image 3 As shown, there is a certain effect on behalf of dilated cardiomyopathy.

[0034] Use of CFTR enhancers in the dilated cardiomyopathy model:

[0035] A CFTR enhancer at a concentration of 8 μm was added to the culture medium of zebrafish model embryos with dilated cardiomyopathy. The treated embryos were treated before 10 hours after fertilization, and the CFTR enhancer was treated for 2 hours.

[0036] Such as Figure 4 As shown, t...

Embodiment 2

[0038] In order to better verify the therapeutic effect of CFTR enhancers on dilated cardiomyopathy, a dilated cardiomyopathy model was first established.

[0039] The dilated cardiomyopathy model is a good simulation of the abnormalities of dilated cardiomyopathy as well as treatment conditions, such as decreased heart rate.

[0040] It was treated with dilated cardiomyopathy drugs, and the decrease in heart rate was restored, which means that dilated cardiomyopathy has a certain effect.

[0041] Use of CFTR enhancers in the dilated cardiomyopathy model:

[0042] The CFTR enhancer at a concentration of 9 μm was added to the culture medium of zebrafish model embryos with dilated cardiomyopathy. The treated embryos were treated before 10 hours after fertilization, and the CFTR enhancer was treated for 4 hours.

[0043] Such as Figure 5 As shown, the average heart rate of wild-type embryos is 156, the average heart rate of dilated cardiomyopathy model embryos is 125, and the ...

Embodiment 3

[0045] In order to better verify the therapeutic effect of CFTR enhancers on dilated cardiomyopathy, a dilated cardiomyopathy model was first established.

[0046] The dilated cardiomyopathy model well mimics the abnormalities of dilated cardiomyopathy as well as treatment conditions, such as reduced fractional shortening.

[0047] The decrease in fractional shortening of the heart was restored by treatment with drugs for dilated cardiomyopathy, indicating that dilated cardiomyopathy has a certain effect.

[0048] Use of CFTR enhancers in the dilated cardiomyopathy model:

[0049] A CFTR enhancer at a concentration of 10 μM was added to the culture medium of zebrafish model embryos with dilated cardiomyopathy. The treated embryos were treated before 10 hours after fertilization, and the CFTR enhancer was treated for 3 hours.

[0050] In the above-mentioned examples: heart enlargement, heart rate reduction, and cardiac fractional shortening reduction in zebrafish embryos can o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for treating dilated cardiomyopathy and an application thereof, belonging to the field of biotechnology. For dilated cardiomyopathy, this application proposes the application of CFTR enhancer in the treatment of dilated cardiomyopathy, and at the same time proposes the treatment of dilated cardiomyopathy. The treatment of dilated cardiomyopathy includes CFTR enhancer. Addition of CFTR enhancers can significantly restore the phenotypes of the zebrafish model, such as heart enlargement, reduced heart rate, and reduced fractional shortening of the heart.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to substances for treating dilated cardiomyopathy and applications thereof, in particular to medicines for treating dilated cardiomyopathy and applications thereof. Background technique [0002] Dilated cardiomyopathy (DCM) is a primary myocardial disease of unknown cause. The disease is characterized by enlargement of the left or right ventricle or both ventricles with hyposystolic function, with or without congestive heart failure. Ventricular or atrial arrhythmias are common. The condition is progressively exacerbated, and death can occur at any stage of the disease. [0003] The publication number is CN101390872A, and the name is an invention patent of ginsenoside Rb1 as a medicine for treating dilated cardiomyopathy, which discloses the application of ginsenoside Rb1 as a medicine for treating dilated cardiomyopathy. The ginsenoside Rb1 has the following functions: long-term admin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/47A61K31/443A61P9/04A61P9/00
CPCA61K31/443A61K31/47A61K45/00A61P9/00A61P9/04
Inventor 孙华钦陈小章周斌张小虎林子媛刘燕燕
Owner THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com